Biotech Growth secures major value from Forte Biosciences takeover
Biotech Growth Trust plc said it will benefit from Argenx SE’s $2.2 billion cash takeover of Forte Biosciences. Argenx offered $77 per share, a 40.5% premium. Forte was about 3% of Biotech Growth’s portfolio. The deal is expected to add about 1.2% to net asset value, after Biotech Growth’s November 2024 entry at $5.55 per share.
How this was made
The 30-second read
Why it matters
The article frames the takeover as a risk-reduction path for early-stage biotech and quantifies the expected NAV accretion for the trust.
Market read
Deal terms and expected NAV uplift create a tradable catalyst for the trust, but execution risk remains unaddressed.
What to watch
No discussion of closing conditions, timeline, or whether the premium is likely to hold through regulatory scrutiny, which can drive deal-spread volatility.
Background
Biotech Growth Trust holds Forte Biosciences (about 3% of its portfolio) and is benefiting from Forte’s agreed cash acquisition by Argenx.
Market effects
Reinforces ongoing consolidation in autoimmune biotech, potentially supporting sentiment for similar clinical-stage targets.
UK-listed biotech trust (BIOG) may see sentiment spillover from London-listed deal coverage.
Cross-border pharma acquisition (Argenx) highlights continued global capital for late-stage autoimmune assets.
Counterpoint
The NAV uplift may be largely priced in quickly; remaining upside depends on deal certainty, regulatory review, and any changes to consideration.
Key entities
- equity trustBiotech Growth Trust plc
UK-listed biotech investment trust expected to see about 1.2% NAV uplift from the Forte takeover.
- biotech companyForte Biosciences
Target of a $2.2B cash takeover; its lead program FB102 is in autoimmune indications.
- acquirerArgenx SE
Agreed to acquire Forte for $77 per share, implying a 40.5% premium.
- investor/managerOrbiMed
Paid $5.55 per share in Forte’s November 2024 private placement, establishing the trust’s entry cost basis.
